Trial Profile
A Phase II, Randomized, Double-Blind, Placebo-Controlled Bronchoscopy Study to Evaluate the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Patients With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms CLAVIER
- Sponsors Roche
- 05 Mar 2018 Results of the nasosorption substudy (n=39) presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 04 Sep 2017 Status changed from active, no longer recruiting to completed.
- 05 Apr 2017 This trial has been completed in the UK (end date: 13 Oct 2016).